BPC-157 and Angiogenic Signaling Models
Reviewing in-vitro literature on VEGFR2 modulation and tenocyte migration models.
- 1BPC-157 consistently upregulates VEGFR2 in endothelial cell models.
- 2Tendon fibroblast outgrowth and migration are enhanced in culture.
- 3Mechanistic theme: angiogenesis-driven repair rather than direct anabolism.
- 4Human PK data are sparse — preclinical signal only.
Overview
Body Protection Compound 157 (BPC-157) is a synthetic pentadecapeptide derived from a protective gastric protein. Across in-vitro and rodent models it is associated with accelerated soft-tissue repair, particularly in tendon, ligament, and gut epithelium.
VEGFR2 and Angiogenesis
A consistent mechanistic theme in the literature is upregulation of VEGFR2 signaling. In endothelial cell models, BPC-157 increases nitric-oxide release and promotes tube formation — both markers of new vessel growth. Tendon fibroblast cultures exposed to BPC-157 show increased outgrowth and migration, consistent with the angiogenic-recovery hypothesis.
Limitations of the Evidence
Most published BPC-157 data are preclinical. Human pharmacokinetic and safety studies are limited, and oral bioavailability remains a question. Researchers should treat the in-vitro findings as hypothesis-generating, not therapeutic.
